Abstract
Background:
Recently, an extensive research has gone into identifying the predictive value of biomarkers for long term mortality in community-acquired pneumonia (CAP).
Objective:
The aim of this study was to evaluate the utility of inflammatory biomarkers measured on admission to predict mortality in patients with CAP.
Methods:
We prospectively included patients over 18 years old for a period of one year. Procalcitonin (PCT), C reactive protein (CRP) and Pro adrenomedullin (ProADM) levels were were compared according to in-hospital mortality, 30, 90 and 180-day mortality, and 1 year mortality, by means of the nonparametric Wilcoxon test. In addition, the predictive accuracy of each biomarker for mortality was analysed by means of logistic regression models, and the AUC was used to measure the predictive ability of each biomarker.
Results:
A total of 610 patients with diagnosis of CAP were included in our study and samples for biomarkers could be extracted in 491 of them. PCT and ProADM levels were significantly higher for short, medium and long term mortality. ProADM was the best biomarker in predicting complications. Figure 1 shows the results of the predictive ability of each biomarker for mortality.
Conclusions:
ProADM is a powerful tool not only for the prediction of short and medium mortality, but also for long term mortality.
- © 2013 ERS
